Amuvatinib(MP-470; MP470; HPK 56)是一种可口服的、具有生物有效性的合成碳硫酰胺，是作用于c-Kit、PDGFα和Flt3等多靶点抑制剂，其IC50值分别是10 nM、40 nM和81 nM，具有潜在的抗肿瘤活性。

参考文献

[1]. Qi W, et al. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. BMC Cancer. 2009 May 11;9:142.

[2]. Welsh JW, et al. The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol. 2009 Dec 22;4:69.

[3]. Zhao H, et al. The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination. Radiother Oncol. 2011 Oct;101(1):59-65.

冰袋运输。粉末直接保存于-20℃，有效期2年。建议分装后-20℃避光保存，避免反复冻融。